{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erbitux&page=12",
    "query": {
      "intervention": "Erbitux",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 322,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erbitux&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erbitux&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T23:05:59.471Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02324608",
      "title": "Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Recurrent Skin Cancer",
        "Squamous Cell Carcinoma of the Skin"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2015-01-30",
      "completion_date": "2023-05-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324608"
    },
    {
      "nct_id": "NCT01602315",
      "title": "A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "BYL719 as film-coated (FC) whole tablets",
          "type": "DRUG"
        },
        {
          "name": "BYL719 as dispersible tablets (DT)",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BYL719 drink suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 179,
      "start_date": "2012-11-12",
      "completion_date": "2016-09-16",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 14,
      "location_summary": "Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602315"
    },
    {
      "nct_id": "NCT00895362",
      "title": "Erlotinib in Combination With Cetuximab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2009-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-07-13",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00895362"
    },
    {
      "nct_id": "NCT00134069",
      "title": "Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Stage III Colon Cancer",
        "Stage III Rectal Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2005-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-16",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Baltimore, Maryland",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134069"
    },
    {
      "nct_id": "NCT01758731",
      "title": "Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2012-10-22",
      "completion_date": "2018-10-31",
      "has_results": true,
      "last_update_posted_date": "2019-09-23",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01758731"
    },
    {
      "nct_id": "NCT00343083",
      "title": "Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Erbitux, Paclitaxel & Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2004-12",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343083"
    },
    {
      "nct_id": "NCT01221753",
      "title": "Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck",
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "IMRT",
          "type": "RADIATION"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2011-07",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2017-12-06",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01221753"
    },
    {
      "nct_id": "NCT05039177",
      "title": "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer",
        "Metastatic Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ERAS-007",
          "type": "DRUG"
        },
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erasca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 101,
      "start_date": "2021-09-20",
      "completion_date": "2026-01-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039177"
    },
    {
      "nct_id": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BMS-986466",
          "type": "DRUG"
        },
        {
          "name": "Adagrasib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2023-11-09",
      "completion_date": "2024-05-13",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06024174"
    },
    {
      "nct_id": "NCT01280643",
      "title": "Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "nucleic acid sequencing",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2010-03",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-15",
      "last_synced_at": "2026-11-11T23:05:59.471Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280643"
    }
  ]
}